Scholarlink

Manipulating the patients’ immune system to produce antibodies that recognize growth factors is an emerging concept. CIMAvax-EGF and HEBERSaVax represent a new class of drugs that target EGF and VEGF, respectively, by conjugating the recombinant antigenic proteins with immunogenic carrier proteins and adjuvants. CIMAvax-EGF generates antibodies against EGF, able to block the EGF-EGFR interaction. This therapeutic vaccine increases the survival of advanced lung cancer patients (non-small histology), when used subsequently to frontline therapy. Patients with high serum EGF had the largest survival advantage. HEBERSaVax induces anti-VEGF antibodies and VEGF-specific cytotoxic T cells. Clinical trials on HEBERSaVax are ongoing in ovarian and fallopian tube and hepatocellular cancer patients. Both vaccines are very safe and induce long-lasting immune response. Further biomarker studies and combination trials with drugs devoted to release the brakes of the immune system, together with the clever insertion of this hormone-depleting immunotherapy into the complex algorithm of cancer treatment, should be the priority. Immune deprivation of growth factors can be an important instrument to transform advanced cancer into a chronic disease.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Immune Deprivation of Growth Factors as Cancer Therapy

  • 工具书词条

  • 发表日期：

    2025年

查看全文
  • Tania Crombet Ramos,
  • Yanelys Morera Díaz,
  • Elia Neninger Vinageras,
  • Orestes Santos Morales,
  • Danay Saavedra Hernández,
  • Mónica Bequet Romero,
  • Javier Sánchez Ramírez,
  • Agustin Lage Dávila

摘要

Manipulating the patients’ immune system to produce antibodies that recognize growth factors is an emerging concept. CIMAvax-EGF and HEBERSaVax represent a new class of drugs that target EGF and VEGF, respectively, by conjugating the recombinant antigenic proteins with immunogenic carrier proteins and adjuvants. CIMAvax-EGF generates antibodies against EGF, able to block the EGF-EGFR interaction. This therapeutic vaccine increases the survival of advanced lung cancer patients (non-small histology), when used subsequently to frontline therapy. Patients with high serum EGF had the largest survival advantage. HEBERSaVax induces anti-VEGF antibodies and VEGF-specific cytotoxic T cells. Clinical trials on HEBERSaVax are ongoing in ovarian and fallopian tube and hepatocellular cancer patients. Both vaccines are very safe and induce long-lasting immune response. Further biomarker studies and combination trials with drugs devoted to release the brakes of the immune system, together with the clever insertion of this hormone-depleting immunotherapy into the complex algorithm of cancer treatment, should be the priority. Immune deprivation of growth factors can be an important instrument to transform advanced cancer into a chronic disease.